REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company
Provided By Globe Newswire
Last update: Jan 13, 2022
-A greater than 50% reduction in SARS-CoV-2 Delta viral load was observed-
-REVTx-99 was tested prior to infection in multiple standard in vitro anti-viral activity assay systems-
Read more at globenewswire.comNASDAQ:REVBW (12/15/2025, 4:00:51 PM)
0.0099
0 (-11.61%)
0.96
-0.09 (-8.57%)
Find more stocks in the Stock Screener
